| |
| Overview |
Airmid is a virtual pharmaceutical start-up focused on developing
and commercializing novel,
safer, more effective treatments for all autoimmune disorders. |
| Large unmet medical needs and very large potential markets |
 |
- More than 20 million Americans suffer from over 80 kinds of autoimmune disorders, including: multiple sclerosis,
psoriasis, rheumatoid arthritis, and type 1 diabetes.
- All existing autoimmune treatments are inadequately effective
- In spite of inadequate treatments, autoimmune drugs generated billions of dollars in revenues last year
(e.g., $4.4bn for MS therapies alone)
- The estimated current annual market for the unmet need is ~ $8 billion
|
| |
|
|
 |
| October 2006 |
AIRMID receives Series A
financing from Biotechnology
Value Fund.
more... |
|
